Introduction Palivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks' gestation who are younger than 12 months at the start of the RSV season. Materials and Methods We hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. Conclusion The RSV hospitalisation rate and LOS were not statistically different in babies under JCVI criteria and additional babies qualifying by AAP criteria. A larger multi-centre prospective study is required to prove health and economic benefits of adopting AAP Palivizumab recommendations.
Introduction Palivizumab is a monoclonal antibody that reduces the likelihood of serious respiratory tract infection by Respiratory Syncytial Virus (RSV) in infants with Chronic Lung Disease (CLD) defined as an ongoing oxygen requirement at 36 weeks corrected gestation. In the UK (UK), Palivizumab is offered to high-risk infants with moderate to severe CLD according to their chronological age at the time of RSV season as per Joint Committee on Vaccination and Immunisation (JCVI) guidelines. The American Academy of Paediatrics, in contrast, recommends Palivizumab prophylaxis for all infants born before 29 weeks' gestation who are younger than 12 months at the start of the RSV season. Materials and Methods We hypothesised that the RSV hospitalisation rate and length of hospital stay (LOS) within the 1 st year of life between preterm babies with CLD immunised according to the JCVI criteria (CLDJCVI) and the additional babies who are considered eligible by the AAP criteria would be comparable. 
Conclusion
The RSV hospitalisation rate was lower in preterm infants who did not qualify for Palivizumab compared to infants who qualified according to JCVI guideline but this difference was not statistically significant. A large prospective multi-centre study is required to ascertain the clinical and economic benefits of including the wider group for Palivizumab prophylaxis.
Introduction Respiratory morbidity is well documented in children with neurological impairment. Early intervention programmes to identify children at high risk are not well established. We proactively reviewed respiratory status of children with severe neurological impairment in local special schools to identify and manage those at high risk.
Methods School nurses identified all children with severe neurological impairment (GMFCS IV and V). All had a multidisciplinary respiratory assessment at school. Data was collected on
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